Target family: Blood coagulation components (type: enzyme)
Target: coagulation factor II, thrombin

Ligand: ximelagatran (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Primary target: no
Median affinity:  -

Ligand: WX-UK1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.300000190734863 pKi
Reference (Journal): Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1.
Published in: Thromb Haemost

Ligand: melagatran (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.699999809265137 pKi
Reference (Journal): Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes.
Published in: Thromb Haemost

Ligand: lepirudin (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1998)
Primary target: yes
Median affinity: 13 pKi
Reference (Journal): Monitoring of Argatroban and Lepirudin: What is the Input of Laboratory Values in &quot;Real Life&quot;?
Published in: Clin Appl Thromb Hemost

Ligand: lepirudin (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1998)
Primary target: yes
Median affinity: 13 pKi
Reference (Journal): Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
Published in: Thromb Haemost

Ligand: Dup-714 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 10.390000343322754 pKi
Reference (Journal): (N-acyl-N-alkyl)glycyl borolysine analogs: A new class of potent thrombin inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: desirudin (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (no history prior to 2003)
Primary target: yes
Median affinity: 12.699999809265137 pKi
Reference (Journal): A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.
Published in: N Engl J Med

Ligand: desirudin (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (no history prior to 2003)
Primary target: yes
Median affinity: 12.699999809265137 pKi
Reference (Journal): Structure-function and refolding studies of the thrombin-specific inhibitor hirudin.
Published in: Haemostasis

Ligand: dabigatran (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.300000190734863 pKi
Reference (Journal): In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate
Published in: Thrombosis and Haemostasis

Ligand: dabigatran (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.300000190734863 pKi
Reference (Journal): Structure-based design of novel potent nonpeptide thrombin inhibitors.
Published in: J Med Chem

Ligand: bivalirudin (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2000)
Primary target: yes
Median affinity: 8.600000381469727 pKi
Reference (Journal): Bivalirudin for patients with acute coronary syndromes.
Published in: N Engl J Med

Ligand: bivalirudin (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2000)
Primary target: yes
Median affinity: 8.600000381469727 pKi
Reference (Journal): Thrombin-specific inhibition by and slow cleavage of hirulog-1.
Published in: Biochem J

Ligand: AZ12971554 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.520000457763672 pKi
Reference (Webpage): AZ12971554.

Ligand: AR-H067637 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.399999618530273 pIC50
Reference (Journal): Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637.
Published in: Thromb Haemost

Ligand: argatroban (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2000)
Primary target: yes
Median affinity: 7.699999809265137 pKi
Reference (Journal): Monitoring of Argatroban and Lepirudin: What is the Input of Laboratory Values in &quot;Real Life&quot;?
Published in: Clin Appl Thromb Hemost

Ligand: argatroban (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2000)
Primary target: yes
Median affinity: 7.699999809265137 pKi
Reference (Journal): Inhibition of collagen-induced platelet aggregation by argatroban in patients with acute cerebral infarction.
Published in: Thromb Res